MicroRNA analysis of gastroenteropancreatic neuroendocrine tumors and metastases

Nadine Zimmermann; Juliana Knief; Tim Kacprowski; Pamela Lazar-Karsten; Tobias Keck; Franck Billmann; Sebastian Schmid; Kim Luley; Hendrik Lehnert; Georg Brabant; Christoph Thorns

doi:10.18632/oncotarget.25357

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MicroRNA analysis of gastroenteropancreatic neuroendocrine tumors and metastases

Nadine Zimmermann, Juliana Knief _, Tim Kacprowski, Pamela Lazar-Karsten, Tobias Keck, Franck Billmann, Sebastian Schmid, Kim Luley, Hendrik Lehnert, Georg Brabant and Christoph Thorns

PDF | HTML | How to cite

Oncotarget. 2018; 9:28379-28390. https://doi.org/10.18632/oncotarget.25357

Metrics: PDF 1315 views | HTML 2224 views | ?

Abstract

Nadine Zimmermann1,*, Juliana Knief1,*, Tim Kacprowski2,*, Pamela Lazar-Karsten1, Tobias Keck3, Franck Billmann3, Sebastian Schmid4, Kim Luley4, Hendrik Lehnert4, Georg Brabant4,* and Christoph Thorns1,*

1Department of Pathology, Section of Hematopathology and Endocrine Pathology, University Hospital of Schleswig-Holstein, Lübeck 23538, Germany

2Department of Functional Genomics, Interfaculty Institute of Genetics and Functional Genomics, University Medicine Greifswald, Greifswald 17475, Germany

3Department of Surgery, University Hospital of Schleswig-Holstein, Lübeck 23538, Germany

4Department of Internal Medicine 1, University Hospital of Schleswig-Holstein, Lübeck 23538, Germany

*These authors contributed equally to this work

Correspondence to:

Juliana Knief, email: [email protected]

Keywords: gastroenteropancreatic tumors; neuroendocrine neoplasias; microRNA; metastatic disease

Received: March 22, 2018 Accepted: April 24, 2018 Published: June 19, 2018

ABSTRACT

The incidence of neuroendocrine neoplasias (NEN) continues to increase. Since the primary tumor cannot be diagnosed in some cases of metastatic disease, new biomarkers are clearly needed to find the most probable site of origin. Tissue samples from 79 patients were analyzed and microRNA profiles were generated from a total of 76 primary tumors, 31 lymph node and 14 solid organ metastases. NEN metastases were associated with elevated levels of miR-30a-5p, miR-210, miR-339-3p, miR-345 and miR-660. Three microRNAs showed a strong correlation between proliferation index and metastatic disease in general (miR-150, miR-21 and miR-660). Further, each anatomic location (primary or metastatic) had one or more site-specific microRNAs more highly expressed in these tissues. Comparison between primary tumors and metastases revealed an overlap only in pancreatic (miR-127) and ileal tumors (let-7g, miR-200a and miR-331). This thorough analysis of gastroenteropancreatic neuroendocrine tumors demonstrates site-specific microRNA profiles, correlation with proliferation indices as well as corresponding nodal and distant metastases. Using microRNA profiling might improve NEN diagnostics by linking metastases to a most probable site of origin.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25357

Publication Alerts

Research Papers:

MicroRNA analysis of gastroenteropancreatic neuroendocrine tumors and metastases

Abstract